Nextera’s CEO, Geir Åge Løset will give the presentation ” Combinatorial specificity profiling and engineering to safeguard and optimize TCR reactivity”
News & Events
Nextera receives Norwegian Research Council funding to expand its NextCore platform with a novel therapeutic T cell receptor discovery pipeline.
Nextera is very pleased to announce that the Norwegian Research Council (NRC) has awarded a prestigious 15.7 MNOK grant funding to expand our NextCore platform with a novel discovery T cell receptor (TCR) discovery pipeline.
At the 12th annual PEGS Europe Summit, Nextera’s CEO GeirÅge Løset will present Nextera’s NextCore drug discovery platform.
This conference is the industry’s event for antibody and protein therapeutic science and technology in Europe. Nextera is in the forefront of such technology development.
CEO Geir Åge Løset and CBO Ole Henrik Brekke will attend the BIO International Convention June 8th – 12th. Book us for a digital meeting and we will present our unique NextCore Immunology platform.
Nextera’s unique pVII phage display technology expands insights into the biology of human FSAP haemostasis
In ChemBioChem we describe the employment of Nextera’s pVII peptide phage display technology in the fine-mapping of FSAP enzyme substrate specificity, which shows surprising new results.
CEO Geir Åge Løset and CBO Ole Henrik Brekke will attend the BIO Europe Spring Digital conference March 23rd – 25th.
The Nextera patent “Multivalent phage display systems and methods” was granted by the USPTO 8.1.2020.
January 1st. Dr. Ole Henrik Brekke joined Nextera as the Chief Business Officer. Ole Henrik has a strong track record in developing companies from the idea stage into successful clinical stage.
A better understanding of immunological principles is at the core of Nextera’s efforts to contribute to robust drug development in complex diseases.